- Home
- PRG vs PCRX Comparison
PRG vs PCRX Comparison
Compare PRG & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- PCRX
- Stock Information
- Founded
- PRG 2020
- PCRX 2006
- Country
- PRG United States
- PCRX United States
- Employees
- PRG N/A
- PCRX N/A
- Industry
- PRG Diversified Commercial Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRG Consumer Discretionary
- PCRX Health Care
- Exchange
- PRG Nasdaq
- PCRX Nasdaq
- Market Cap
- PRG 1.4B
- PCRX 1.2B
- IPO Year
- PRG N/A
- PCRX 2011
- Fundamental
- Price
- PRG $29.62
- PCRX $23.96
- Analyst Decision
- PRG Buy
- PCRX Strong Buy
- Analyst Count
- PRG 6
- PCRX 6
- Target Price
- PRG $35.00
- PCRX $33.83
- AVG Volume (30 Days)
- PRG 429.0K
- PCRX 802.2K
- Earning Date
- PRG 10-22-2025
- PCRX 11-06-2025
- Dividend Yield
- PRG 1.78%
- PCRX N/A
- EPS Growth
- PRG 10.59
- PCRX N/A
- EPS
- PRG 3.96
- PCRX 0.47
- Revenue
- PRG $2,507,179,000.00
- PCRX $716,791,000.00
- Revenue This Year
- PRG $1.28
- PCRX $7.27
- Revenue Next Year
- PRG $0.64
- PCRX $10.18
- P/E Ratio
- PRG $7.36
- PCRX $50.52
- Revenue Growth
- PRG 3.71
- PCRX 3.14
- 52 Week Low
- PRG $23.50
- PCRX $16.29
- 52 Week High
- PRG $49.50
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- PRG 55.27
- PCRX 56.14
- Support Level
- PRG $25.80
- PCRX $22.29
- Resistance Level
- PRG $28.54
- PCRX $24.95
- Average True Range (ATR)
- PRG 0.87
- PCRX 1.23
- MACD
- PRG 0.39
- PCRX 0.09
- Stochastic Oscillator
- PRG 96.57
- PCRX 78.19
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.